Basics Aurinia Pharmaceuticals Inc Aurinia Pharmaceuticals Inc is a clinical stage pharmaceutical company. The firm is engaged in the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis. IPO Date: September 1, 2014 Sector: Healthcare Industry: Biotech Market Cap: $1.21B Activated in VL: True Average Daily Range Avg Daily Range: $0.23 | 2.72% Avg Daily Range (30 D): $0.21 | 2.47% Avg Daily Range (90 D): $0.15 | 1.87% Institutional Daily Volume Avg Daily Volume: 1.73M Avg Daily Volume (30 D): 1.51M Avg Daily Volume (90 D): 1.25M Trade Size Avg Trade Size (Sh.): 171 Avg Trade Size (Sh.) (30 D): 119 Avg Trade Size (Sh.) (90 D): 108 Institutional Trades Total Inst.Trades: 2,326 Avg Inst. Trade: $1.22M Avg Inst. Trade (30 D): $1.53M Avg Inst. Trade (90 D): $1.34M Avg Inst. Trade Volume: .11M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.28M Avg Closing Trade (30 D): $1.38M Avg Closing Trade (90 D): $1.1M Avg Closing Volume: 128.13K     News Jan 8, 2025 @ 8:35 PM New American College of Rheumatology Guidelines fo... Source: Spherix Global Insights Oct 2, 2024 @ 1:48 PM Corporate and Individual Donations Provide Much-Ne... Source: American Kidney Fund Jun 17, 2024 @ 8:46 AM Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump... Source: Zacks Equity Research May 7, 2024 @ 1:55 PM How Much Upside is Left in Aurinia (AUPH)? Wall St... Source: Zacks Equity Research May 2, 2024 @ 11:10 AM Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, To... Source: Zacks Equity Research Financials   TTM Q1 2025 Q3 2024 Basic EPS $.17 $.1 Diluted EPS $.16 $.1 Revenue $ $ 62.47M $ 67.77M Gross Profit $ $ 53.89M $ 61.74M Net Income / Loss $ $ 23.34M $ 14.35M Operating Income / Loss $ $ 21.85M $ 11.75M Cost of Revenue $ $ 8.57M $ 6.04M Net Cash Flow $ $ -17.01M $ 3.74M PE Ratio     Splits Oct 23, 2013:   1:50